CIGNA (CI) Price Target Raised to $237.00
CIGNA (NYSE:CI) had its price objective lifted by stock analysts at Credit Suisse Group to $237.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The brokerage presently has an “outperform” rating on the health services provider’s stock. Credit Suisse Group’s price objective would suggest a potential upside of 19.79% from the stock’s current price.
Several other analysts have also issued reports on CI. Zacks Investment Research upgraded shares of CIGNA from a “hold” rating to a “buy” rating and set a $197.00 price target on the stock in a research report on Monday, May 28th. Goldman Sachs Group upgraded shares of CIGNA from a “neutral” rating to a “buy” rating and raised their price target for the stock from $193.00 to $212.00 in a research report on Wednesday, June 6th. ValuEngine lowered shares of CIGNA from a “hold” rating to a “sell” rating in a research report on Monday, July 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $224.00 price objective on shares of CIGNA in a report on Friday, August 3rd. Finally, SunTrust Banks raised their price objective on shares of CIGNA to $244.00 and gave the stock a “buy” rating in a report on Friday, August 3rd. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $227.00.
NYSE CI opened at $197.84 on Tuesday. The company has a current ratio of 0.38, a quick ratio of 0.38 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $47.48 billion, a price-to-earnings ratio of 18.91, a P/E/G ratio of 1.15 and a beta of 0.63. CIGNA has a 52-week low of $163.02 and a 52-week high of $227.13.
In other CIGNA news, CFO Eric P. Palmer acquired 2,828 shares of CIGNA stock in a transaction dated Tuesday, July 31st. The stock was bought at an average cost of $177.61 per share, with a total value of $502,281.08. Following the acquisition, the chief financial officer now owns 9,678 shares of the company’s stock, valued at $1,718,909.58. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.10% of the stock is currently owned by company insiders.
Hedge funds have recently made changes to their positions in the stock. Flagship Harbor Advisors LLC acquired a new stake in CIGNA in the 2nd quarter valued at about $102,000. Sun Life Financial INC increased its position in CIGNA by 254.3% in the 2nd quarter. Sun Life Financial INC now owns 659 shares of the health services provider’s stock valued at $112,000 after acquiring an additional 473 shares in the last quarter. Signaturefd LLC acquired a new stake in CIGNA in the 1st quarter valued at about $115,000. Elmwood Wealth Management Inc. acquired a new stake in CIGNA in the 1st quarter valued at about $117,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its position in CIGNA by 3,122.7% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 709 shares of the health services provider’s stock valued at $120,000 after acquiring an additional 687 shares in the last quarter. 89.39% of the stock is owned by hedge funds and other institutional investors.
CIGNA Company Profile
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers.
Recommended Story: Outstanding Shares
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.